BEBIG Medical GmbH provides products and services related to prostate and ophthalmic brachytherapy, as well as HDR brachytherapy and X-ray therapy.

BEBIG Medical GmbH

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

Metric
Company Name	BEBIG Medical GmbH	ICU Medical, Inc.
Symbol		ICUI
MSH ID	COM:BEBIG	COM:ICUMED
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Medical - Instruments & Supplies
Country	DE	US
Stage
Employee Count		14K
Website	bebig.com	icumed.com
LinkedIn
Founders

Metric
Market Cap		3.00B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		2.26B
Revenue (LTM)
Revenue (NTM)
Gross Profit		709.82M
EBITDA		290.37M
Operating Income		39.69M
Net Income		-29.66M
EPS		-1.23
Diluted EPS		-1.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.32
Operating Profit Margin		0.01
EBITDA Margin		0.13
Net Profit Margin		-0.01
Return on Equity		-0.01
Return on Assets		-0.01
Return on Capital Employed		0.01

BEBI

COM:BEBIG

BEBIG Medical GmbH

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-74.93
P/B Ratio		1.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		1.95
EV Multiple		13.73

Metric
Days Sales Outstanding		26.26
Days Payables Outstanding		36.18
Days Inventory Outstanding		168.88
Operating Cycle		195.42
Cash Conversion Cycle		159.71
Asset Turnover		0.54

Metric
Operating Cash Flow		166.20M
Free Cash Flow		72.53M
Cash Flow to Debt		0.16
Operating Cash Flow/Sales		0.11
Free Cash Flow Yield		-0.01

Metric
Cash & Equivalents		254.22M
Accounts Receivable		48.63M
Inventory		709.36M
Goodwill		1.47B
Debt to Capitalization		0.45
Debt to Assets		0.37
Current Ratio		2.63
Quick Ratio		1.42

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.02
R&D to Revenue		0.04
SG&A to Revenue